Quick filters
- Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement PR Newswire | Wednesday April 3, 2013 4:23PM
- European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Company's empagliflozin*, an investigational type 2 diabetes treatment PR Newswire | Tuesday March 26, 2013 11:23AM
- American College of Endocrinology (ACE) to emphasize emergency planning for people with diabetes at National Hurricane Conference PR Newswire | Monday March 25, 2013 8:00AM
- Boehringer Ingelheim and Lilly initiate MARLINA clinical trial to evaluate use of Tradjenta® (linagliptin) tablets in patients with type 2 diabetes and albuminuria PR Newswire | Tuesday March 19, 2013 8:00AM
- New Study of Cialis® (tadalafil) Tablets Co-administered with Finasteride Meets Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia PR Newswire | Monday March 18, 2013 11:16AM
- New Superiority Trial Showed LIVALO® (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg PR Newswire | Thursday March 7, 2013 6:30AM
- Lilly Sets Date for 2013 Diabetes Pipeline Update to the Media and Investment Community PR Newswire | Tuesday March 5, 2013 8:00AM
- Lilly's Team Solutions and Solutions for Wellness Resources for Serious Mental Illness Added to SAMHSA's Distinguished National Registry PR Newswire | Wednesday February 20, 2013 8:00AM
- Eli Lilly CEO warns Canadian court rulings put jobs at risk Globe and Mail | Thursday February 14, 2013 5:00AM
- QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics PR Newswire | Wednesday February 13, 2013 4:00PM
- Lilly Diabetes celebrates six years of scholarship support for American Diabetes Association diabetes summer camps by sending 90 children to camp in 2013 PR Newswire | Wednesday February 13, 2013 8:00AM
- Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results PR Newswire | Thursday February 7, 2013 8:05AM
- Lilly Recognized for Fifth Straight Year on NAFE's 'Top 50 Companies for Executive Women' PR Newswire | Tuesday February 5, 2013 7:00AM
- Premarket: RIM rises; futures slip on GDP surprise Globe and Mail | Wednesday January 30, 2013 8:00AM
- At the open: TSX mildly higher but RIM shares down again Globe and Mail | Tuesday January 29, 2013 9:53AM
- Premarket: Stocks head for lower opening, despite several earnings beats Globe and Mail | Tuesday January 29, 2013 7:39AM
- Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance PR Newswire | Tuesday January 29, 2013 6:30AM
- Amyvid? (Florbetapir F 18 Injection) Approved in European Union for Use in Patients With Cognitive Impairment Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Impairment PR Newswire | Tuesday January 15, 2013 3:36PM
- Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin PR Newswire | Monday January 7, 2013 8:52AM
- Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog PR Newswire | Monday January 7, 2013 8:00AM
Live Discussion of LLY on StockTwits